Enorama Pharma AB Total Assets
Enorama Pharma AB total assets. Based on the latest financial reports, Enorama Pharma AB (ERMA) holds total assets worth Skr6.95 Million SEK (≈ $748.15K USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Enorama Pharma AB market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Enorama Pharma AB (2014–2025)
Total assets of Enorama Pharma AB from 2014 to 2025. This chart illustrates how Enorama Pharma AB's total assets have evolved over time, based on quarterly financial data. See current stock price of Enorama Pharma AB for real-time trading data and today's change.
Enorama Pharma AB - Asset Composition Analysis
Enorama Pharma AB Total Assets Breakdown (December 2025)
Enorama Pharma AB total assets breakdown as of December 2025. Enorama Pharma AB's total assets of Skr6.95 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 36.8% |
| Accounts Receivable | Skr2.65 Million | 32.0% |
| Inventory | Skr1.75 Million | 21.2% |
| Property, Plant & Equipment | Skr12.00K | 0.2% |
| Intangible Assets | Skr254.00K | 3.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Enorama Pharma AB working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Enorama Pharma AB's current assets represent 96.8% of total assets in 2025, an increase from 0.7% in 2014.
- Cash Position: Cash and equivalents constituted 36.8% of total assets in 2025, up from 0.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 32.0% of total assets.
Enorama Pharma AB Competitors by Total Assets
Key competitors of Enorama Pharma AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Enorama Pharma AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.21 | 0.53 | 0.60 |
| Quick Ratio | 0.16 | 0.33 | 0.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr-25.88 Million | Skr-7.81 Million | Skr-8.38 Million |
Enorama Pharma AB - Advanced Valuation Insights
This section examines the relationship between Enorama Pharma AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.30 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | -48.0% |
| Total Assets | Skr8.26 Million |
| Market Capitalization | $6.34 Million USD |
Valuation Analysis
Below Book Valuation: The market values Enorama Pharma AB's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Enorama Pharma AB's assets decreased by 48.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Enorama Pharma AB (2014–2025)
The table below shows the annual total assets of Enorama Pharma AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr8.26 Million ≈ $889.12K |
-48.02% |
| 2024-12-31 | Skr15.89 Million ≈ $1.71 Million |
-53.78% |
| 2023-12-31 | Skr34.38 Million ≈ $3.70 Million |
-29.42% |
| 2022-12-31 | Skr48.72 Million ≈ $5.24 Million |
-4.34% |
| 2021-12-31 | Skr50.93 Million ≈ $5.48 Million |
+24.52% |
| 2020-12-31 | Skr40.91 Million ≈ $4.40 Million |
-3.94% |
| 2019-12-31 | Skr42.58 Million ≈ $4.58 Million |
+9.67% |
| 2018-12-31 | Skr38.83 Million ≈ $4.18 Million |
+150.72% |
| 2017-12-31 | Skr15.49 Million ≈ $1.67 Million |
+13.66% |
| 2016-12-31 | Skr13.63 Million ≈ $1.47 Million |
+48.63% |
| 2015-12-31 | Skr9.17 Million ≈ $986.62K |
+148.19% |
| 2014-12-31 | Skr3.69 Million ≈ $397.53K |
-- |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells tobacco-free white snus in Sweden. It offers its products under the NIC-S brand name. The company was incorporated in 2006 and is based in Stockholm, Sweden.